Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery

医学 肝细胞癌 病态的 放射科 癌 内科学 肿瘤科 外科
作者
Zhen-Xin Zeng,Jiayi Wu,Junyi Wu,Zhibo Zhang,Kai Wang,Shao-Wu Zhuang,Bin Li,Jianyin Zhou,Zhong-Tai Lin,Shu-Qun Li,Yinan Li,Yang-Kai Fu,Mao-Lin Yan
出处
期刊:Liver cancer [Karger Publishers]
卷期号:: 1-11
标识
DOI:10.1159/000536376
摘要

<b><i>Introduction:</i></b> Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor (triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular carcinoma (uHCC). We aimed to explore the prognostic value of pathological response (PR) in patients with initially uHCC who underwent conversion surgery following triple therapy and identify predictors of major pathological response (MPR). <b><i>Methods:</i></b> A total of 76 patients with initially uHCC who underwent conversion surgery following triple therapy were retrospectively analyzed. PR was calculated as the proportion of nonviable tumor cell surface area of the whole tumor bed surface area. MPR was identified when PR was ≥90%. Pathological complete response (pCR) was defined as the absence of viable tumor cells. <b><i>Results:</i></b> MPR and pCR were identified in 53 (69.7%) and 25 (32.9%) patients, respectively. The 1- and 2-year overall survival in patients with MPR were significantly higher than in those without MPR (100.0% and 91.3% vs. 67.7% and 19.4%; <i>p</i> &lt; 0.001). The corresponding recurrence-free survival was also improved in patients with MPR compared to those without (75.9% and 50.8% vs. 22.3% and 11.2%; <i>p</i> &lt; 0.001). Similar results were observed among patients with pCR and those without. Patients who achieved MPR without pCR exhibited survival rates comparable to those of patients who achieved pCR. Baseline neutrophil-to-lymphocyte ratio ≥2.6 (<i>p</i> = 0.016) and preoperative alpha-fetoprotein level ≥400 ng/mL (<i>p</i> = 0.015) were independent predictors of MPR. <b><i>Conclusion:</i></b> The presence of MPR or pCR could improve prognosis in patients with initially uHCC who underwent conversion surgery following triple therapy. The PR may become a surrogate marker for predicting the prognosis of these patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
繁荣的亦云完成签到,获得积分10
1秒前
1秒前
KScrazy发布了新的文献求助10
1秒前
1秒前
无极微光的应助被zjq采纳,获得30
1秒前
高大以南发布了新的文献求助10
2秒前
2秒前
桐桐的应助被阿氏之光采纳,获得10
2秒前
NexusExplorer的应助被如何让人采纳,获得10
2秒前
852的应助被红颜刹朱槿采纳,获得10
2秒前
3秒前
tttt完成签到 ,获得积分10
3秒前
黄平平发布了新的文献求助10
3秒前
3秒前
3秒前
Giaogiao完成签到,获得积分20
3秒前
Maestro_S的应助被时尚雪莲采纳,获得10
4秒前
leajay发布了新的文献求助10
4秒前
amour发布了新的文献求助10
4秒前
晖少完成签到,获得积分10
4秒前
情怀的应助被yan采纳,获得10
4秒前
4秒前
情怀的应助被文武大帝采纳,获得10
5秒前
和谐的灵波完成签到,获得积分10
5秒前
lhz完成签到,获得积分10
5秒前
Waa发布了新的文献求助10
6秒前
waiting完成签到,获得积分10
6秒前
小二郎的应助被jiangjiang采纳,获得10
6秒前
冉景发布了新的文献求助10
6秒前
cz发布了新的文献求助30
7秒前
爱搞科研的小Q完成签到,获得积分10
7秒前
7秒前
pluto的应助被arsheng采纳,获得10
7秒前
Vicki完成签到,获得积分10
7秒前
easton完成签到,获得积分10
7秒前
7秒前
淮qaq完成签到,获得积分20
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949